A randomized phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
This randomized phase II/III trial studies how well cediranib maleate and olaparib work when
given together or separately, and compares them to standard chemotherapy in treating patients
with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving
chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while
being treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate
and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth.
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading. It
is not yet known whether giving cediranib maleate and olaparib together may cause more damage
to cancer cells when compared to either drug alone or standard chemotherapy.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.